Aficamten Crystalline Form Z1 for Stable Drug Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have limited disclosure on the stability and suitability of polymorphic forms of aficamten, which affects pharmaceutical parameters such as stability, storage, density, compressibility, and dissolution rates, necessitating a comprehensive polymorph screening for a stable and suitable crystalline form for drug development.
Innovation Solution
The development of crystalline Form Z1 of aficamten, characterized by specific X-ray diffraction peaks and high chemical purity, which remains stable for at least 6 months under certain conditions and does not convert into other forms, along with a preparation process involving solvent treatment and removal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If comprehensive polymorph screening is performed to find a stable crystalline form, then stability and suitability for drug development are improved, but time and resource consumption increase
Solution Approach 1:
The patent performs comprehensive polymorph screening and stability assessment in advance during the development phase, identifying Form Z1 as the most stable form before commercialization. This preliminary action ensures long-term stability and reduces the need for future polymorph conversions or reformulations, resolving the contradiction by investing time upfront to gain reliability long-term.
2Reliability
If a stable crystalline form is selected for drug development, then pharmaceutical parameters such as stability and storage are improved, but manufacturing complexity increases due to the need for comprehensive screening
Solution Approach 1:
The patent systematically varies crystallization parameters (solvent type, temperature, pH, concentration) to identify and characterize different polymorphic forms. By understanding how these parameters affect polymorph formation, the patent establishes controlled manufacturing conditions that reliably produce Form Z1, reducing complexity by creating a predictable, parameter-based manufacturing approach.
3Productivity
If polymorphic forms with different physical properties are used, then dissolution rates and bioavailability are improved, but stability and chemical reactivity become unpredictable
Solution Approach 1:
The patent characterizes the local molecular arrangement and intermolecular interactions within Form Z1's crystal lattice through detailed structural analysis. By understanding the specific local quality of Form Z1's crystal structure, the patent explains why this particular polymorph achieves an optimal balance between dissolution rate (through its crystal packing) and stability (through its energetic favorability), resolving the contradiction by selecting a form with locally optimized properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Crystalline Form Z1 of aficamten maintains high chemical purity and stability, ensuring effective pharmaceutical performance and suitability for drug development, with a process that enhances its stability and purity.
Implementation Method 1
having peaks expressed in degree(s) 2θ at about 3.8°, 11.2°, 12.9°, and 22.5°±0.2° with an absence of a peak at 14.4°±0.2°, when measured by X-ray powder diffraction
Implementation Method 2
having a differential scanning calorimetry (DSC) having an endothermic peak at about 200±3° C. at a heating rate of 10° C./min
Data Source
AI summary
The present invention relates to crystalline Form of aficamten. In particular, the present invention relates to crystalline Form Z1 of aficamten and process for preparation thereof. The present invention also relates to a pharmaceutical composition comprising the crystalline Form Z1 of aficamten. The invention also relates to the stable crystalline Form Z1 of aficamten.